Fluvoxamine Attenuates Liver Injury in Lipopolysaccharide‐Induced Sepsis: Via Nrf2/HO‐1 Pathway
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Rahime Aslankoc und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Sepsis, Fluvoxamine, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Scientific Research Fund of Süleyman Demirel University.
Themen: Sepsis
Abstract (Originalsprache)
The search for new treatments for sepsis is a pivotal subject of survey owing to the high mortality of sepsis. Sepsis can cause serious injury to many vital organs, including the liver. This study investigated the potential therapeutic impacts of fluvoxamine (FLV) against liver injury in a lipopolysaccharide (LPS)‐induced sepsis model. Thirty‐two female Wistar Albino rats were divided into four equal groups: control, LPS (5 mg/kg, i.p., single dose), LPS + FLV(5 mg/kg, i.p., single dose+50 mg/kg, i.p., single dose, 30 min before LPS application) and FLV(50 mg/kg, i.p., single dose). Six hours after LPS application, blood and liver tissues were gathered under anesthesia for biochemical, histopathological, and immunohistochemical analyses. The RT‐qPCR analyzed the mRNA expression of nuclear factor erythroid 2–related factor 2 (Nrf2), glycogen synthase kinase‐3 (GSK3ß), kelch‐like ECH–associated protein 1 (Keap1), and heme oxygenase‐1 (HO‐1). LPS administration caused significant histopathological changes in the liver and increased oxidative stress. It increased the number of TNF‐α, osteopontin (OPN), and serum amyloid A (SAA) immune positive cells associated with inflammation and decreased Nrf2, GSK3ß, Keap1, and HO‐1 gene expressions associated with antioxidant defense. Additionally, serum alanine aminotransferase (ALT) level significantly increased. In the LPS + FLV and FLV groups, improvement in histopathological findings and a significant decrease in oxidative stress were detected. TNF‐α, OPN, and SAA expression decreased, and Nrf2, GSK3ß, Keap1, and HO‐1 gene expressions increased. The decrease in serum aspartate aminotransferase (AST) and ALT was found to be significant only in the FLV group. Our findings therefore provide new evidence that FLV reduces LPS‐induced liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
- Department of Pathology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey.
- Department of Anesthesiology and Reanimation, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
- Innovative Technologies Application and Research Center, Genetic Research Unit, Süleyman Demirel University, Isparta, Turkey.
ORCID-Profile: Rahime Aslankoc, Ozlem Ozmen, Cahide Aslan, Oguzhan Kavrik, Okan Sancer
Förderung
- Scientific Research Fund of Süleyman Demirel University
Zitieren
APA
Aslankoc, R., Ozmen, O., Karabacak, P., Aslan, C., Kavrik, O., & Sancer, O. (2025). Fluvoxamine Attenuates Liver Injury in Lipopolysaccharide‐Induced Sepsis: Via Nrf2/HO‐1 Pathway. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70031
Vancouver
Aslankoc R, Ozmen O, Karabacak P, Aslan C, Kavrik O, Sancer O. Fluvoxamine Attenuates Liver Injury in Lipopolysaccharide‐Induced Sepsis: Via Nrf2/HO‐1 Pathway. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70031
BibTeX
@article{Aslankoc2025,
author = {Aslankoc, Rahime and Ozmen, Ozlem and Karabacak, Pınar and Aslan, Cahide and Kavrik, Oguzhan and Sancer, Okan},
title = {Fluvoxamine Attenuates Liver Injury in Lipopolysaccharide‐Induced Sepsis: Via Nrf2/HO‐1 Pathway},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70031}
}
EUVIMED